These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 29603888)

  • 1. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.
    Luz PM; Osher B; Grinsztejn B; Maclean RL; Losina E; Stern ME; Struchiner CJ; Parker RA; Freedberg KA; Mesquita F; Walensky RP; Veloso VG; Paltiel AD
    J Int AIDS Soc; 2018 Mar; 21(3):e25096. PubMed ID: 29603888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
    Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
    Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
    J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
    Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
    Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
    Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
    Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
    J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan.
    Mizushima D; Nagai Y; Mezzio D; Harada K; Piao Y; Barnieh L; El Moustaid F; Cawson M; Taniguchi T
    J Med Econ; 2023; 26(1):886-893. PubMed ID: 37421417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.
    Kazemian P; Costantini S; Kumarasamy N; Paltiel AD; Mayer KH; Chandhiok N; Walensky RP; Freedberg KA
    Clin Infect Dis; 2020 Feb; 70(4):633-642. PubMed ID: 30921454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges.
    Veloso VG; Mesquita F; Grinsztejn B
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20010. PubMed ID: 26198347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
    Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP
    Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
    Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
    Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel.
    Ginsberg GM; Chemtob D
    BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a pre-exposure prophylaxis programme for men who have sex with men and transgender women in Thailand: learning through the HIV prevention cascade lens.
    Ramautarsing RA; Meksena R; Sungsing T; Chinbunchorn T; Sangprasert T; Fungfoosri O; Meekrua D; Sumalu S; Pasansai T; Bunainso W; Wongsri T; Mainoy N; Colby D; Avery M; Mills S; Vannakit R; Phanuphak P; Phanuphak N
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25540. PubMed ID: 32602660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016.
    Ong KJ; Desai S; Field N; Desai M; Nardone A; van Hoek AJ; Gill ON
    Euro Surveill; 2017 Oct; 22(42):. PubMed ID: 29067902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PrEP interest and HIV-1 incidence among MSM and transgender women in coastal Kenya.
    Kimani M; van der Elst EM; Chiro O; Oduor C; Wahome E; Kazungu W; Shally M; Rinke de Wit TF; Graham SM; Operario D; Sanders EJ
    J Int AIDS Soc; 2019 Jun; 22(6):e25323. PubMed ID: 31194291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.
    Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L
    Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.